June 20, 2017
Novartis confirms macular degeneration treatments with 1800 patients globally, production filing in 2018
The world’s Ophtamology leader Novartis has reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two Phase III studies, HAWK and HARRIER, with RTH258 3 mg, evaluated in HAWK, also met these endpoints.
